Related Experiment Video
Updated: Dec 2, 2025

Author Spotlight: Unlocking Insights into the Immune Cell Landscape of Tumors
Published on: August 18, 2023
[Biomarkers for Immunotherapy Based on the Local Microenvironment of Gastric Cancer]
Hiroaki Tanaka1, Yoshihito Yamakoshi, Chie Sakimura
1Dept. of Gastroenterological Surgery, Osaka City University Graduate School of Medicine.
Abstract:
Currently, the immunotherapy approved for gastric cancer is immune checkpoint blockade( ICB) therapy. The effects of ICB depend on the T cell-mediated immune response elicited at the cancer site. Based on the results of previous clinical trials, it is clear that an enhanced immune response to cancer improves prognosis. Thus, the development of biomarkers to predict local immune responses may increase the significance of future immunotherapy for gastric cancer. Biomarker research has clearly progressed with the rapid development of genetic analysis technologies, enabling the analysis of data from clinical trials. Not only the molecular biomarkers known to date for ICB biomarkers, but immune cells that influence ICB therapy are also reviewed in this article.
More Related Videos
Related Concept Videos
The Tumor Microenvironment
Tumor Immunotherapy

